Business Wire

CA-ASM-GLOBAL

23.5.2024 15:01:28 CEST | Business Wire | Press release

Share
THE ROLLING STONES ADD ADDITIONAL TOUR DATE IN MISSOURI FOR THE STONES TOUR ‘24 HACKNEY DIAMONDS

Today, The Rolling Stones have announced they will be extending the STONES TOUR ’24 HACKNEY DIAMONDS with an additional stop in Ridgedale, Missouri, on July 21 at Thunder Ridge Nature Arena. Tickets are on sale Friday, May 31, 2024, at 10 a.m. local time. For ticketing information, please visit www.rollingstones.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523672007/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Mick, Keith and Ronnie kicked off their wildly anticipated tour in Houston, Texas, last month and have brought their legendary show to cities across the United States, including the New Orleans Jazz and Heritage Festival, treating fans to their iconic hits and new music from their critically acclaimed new album HACKNEY DIAMONDS. The STONES TOUR ‘24 HACKNEY DIAMONDS will make stops in 12 more cities across the U.S. and Canada with stops in East Rutherford, Foxboro, Orlando, Atlanta, Philadelphia, Cleveland, Denver, Chicago, Vancouver, Los Angeles and Santa Clara with a final stop in Ridgedale. Full tour routing is below.

Hackney Diamonds is their first studio set of new material since 2005’s A Bigger Bang. Since then, the Stones have continued to smash box office records on a series of global sell-out tours and released 2016’s GRAMMY® Award winning Blue & Lonesome, which featured their brilliant versions of many of the blues tracks that helped shape their sound and topped album charts around the world. In 2022, they thrilled European audiences totaling nearly a quarter of a million on the anniversary Sixty tour. The Rolling Stones have sold over 250 million albums worldwide.

Thunder Ridge Nature Arena — a decade in planning, development and construction with the ambition to create America’s most beautiful outdoor amphitheater — is scheduled to open this May as a one-of-a-kind immersive outdoor “musical postcard from Mother Nature.” Located in Ridgedale, Missouri, just a few miles from Branson, Thunder Ridge Nature Arena is described by its creator and visionary — noted conservationist and Bass Pro Shops founder Johnny Morris as a “gift of the Ozarks to the world.” It is the only venue on Earth completely dedicated to conservation.

AEG Presents’ Concerts West is the promoter of the Stones Tour ’24 Hackney Diamonds. For tickets and information, head to www.rollingstones.com.

THE ROLLING STONES – STONES TOUR ‘24 HACKNEY DIAMONDS
Sponsored by AARP

Thursday, May 23, 2024

MetLife Stadium

East Rutherford, NJ

Sunday, May 26, 2024

MetLife Stadium

East Rutherford, NJ

Thursday, May 30, 2024

Gillette Stadium

Foxboro, MA

Monday, June 3, 2024

Camping World Stadium

Orlando, FL

Friday, June 7, 2024

Mercedes-Benz Stadium

Atlanta, GA

Tuesday, June 11, 2024

Lincoln Financial Field

Philadelphia, PA

Saturday, June 15, 2024

Cleveland Browns Stadium

Cleveland, OH

Thursday, June 20, 2024

Empower Field at Mile High

Denver, CO

Thursday, June 27, 2024

Soldier Field

Chicago, IL

Sunday, June 30, 2024

Soldier Field

Chicago, IL                    

Friday, July 5, 2024

BC Place

Vancouver, BC

Wednesday, July 10, 2024

SoFi Stadium

Los Angeles, CA

Saturday, July 13, 2024

SoFi Stadium

Los Angeles, CA

Wednesday, July 17, 2024

Levi’s® Stadium

Santa Clara, CA

Sunday, July 21, 2024

Thunder Ridge Nature Arena

Ridgedale, MO

 www.youtube.com/user/therollingstones
www.instagram.com/therollingstones
www.tiktok.com/@therollingstones
www.facebook.com/therollingstones
www.twitter.com/rollingstones
www.aegpresents.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523672007/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye